



(51) International Patent Classification:

C12N 5/0783 (2010.01) *G16H 20/00* (2018.01)
G16H 10/00 (2018.01) *G16H 20/10* (2018.01)
A61P 35/00 (2006.01) *G16H 20/17* (2018.01)

(21) International Application Number:

PCT/US2021/028709

(22) International Filing Date:

22 April 2021 (22.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/013,942	22 April 2020 (22.04.2020)	US
63/155,711	02 March 2021 (02.03.2021)	US
63/159,806	11 March 2021 (11.03.2021)	US

(71) Applicant: **IOVANCE BIOTHERAPEUTICS, INC.**
 [US/US]: 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US).

(72) Inventors: **BROOKS, Anne**; c/o Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). **MACRIDES, Steve**; c/o Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). **LANZI, Kristin**; c/o Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US).

(74) Agent: **UPADHYE, Kalpesh, V.** et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004-2541 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY




FIG. 1

(57) Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))